<DOC>
	<DOCNO>NCT02424539</DOCNO>
	<brief_summary>This Phase IV interventional study multi-center , randomize , double-blind , placebo-controlled parallel study evaluate efficacy safety FFNS110 mcg 55 mcg daily versus vehicle placebo aqueous nasal spray chinese pediatric subject age 2 12 year AR . This study comprise screen run-in period ( 4 to14 day ) , double-blind treatment period ( 28 day ) follow period ( 3 to7 day ) . Subjects enter study participate maximum 50 day , include five clinical visit follow-up contact . The study plan enroll approximately 360 subject .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Fluticasone Furoate Nasal Sprays ( FFNS ) 55 Microgram ( mcg ) 110 mcg Chinese Pediatric Subjects With Allergic Rhinitis ( AR )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Signed date informed consent obtain subject 's parent/guardian . Chinese male nonchild bear potential female pediatric outpatient subject &gt; =2 &lt; =12 year age Visit 2 . Diagnosis AR : Subjects must diagnosis intermittent allergy rhinitis ( IAR ) [ symptom present &lt; 4 day week , &lt; 4 week ] persistent allergic rhinitis ( PER ) [ symptom present &gt; =4 day week , &gt; =4 week ] symptom , physical sign skin prick test ( SPT ) serumspecific immunoglobulin E ( IgE ) test . Subjects must 2 symptom AR ( watery rhinorrhea , nasal obstruction , nasal itch sneeze ) , also present consecutively accumulatively 1 hour day prior Visit 1 , or/and concomitant ocular symptom : ocular itching , red eye , watery eye etc . The physical sign include : nasal mucosa pale , oedema , nasal secretion . Allergic shiner allergic crease severity pediatric . A documented positive prick skin test positive serum specific IgE test use standardize allergen extract . A positive skin test define allergen wheal &gt; =3 millimeter ( mm ) , histamine &gt; =3 mm . Subjects nasal symptom describe or/and associate ocular symptom , well nasal sign one laboratory test positive demonstrate SPT represent positive response serumspecific IgE testing represent positive response within 12 month prior Visit 1 . Subject must willing maintain environment throughout study . Subject and/or subject 's parent/guardian understands willing , able likely comply study procedure restriction well manage study drug administration . Concomitant Medical Conditions : ( ) Significant concomitant medical condition define historical current evidence clinically significant uncontrolled disease body system . Significant defined disease , opinion investigator , would confound interpretation study result disease/condition exacerbate study : significant renal impairment , base opinion investigator , would preclude subject ' participation study current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator assessment ) . ( NOTES : Stable chronic liver disease generally define absence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , oesophageal gastric varix , persistent jaundice , cirrhosis Chronic stable hepatitis B C [ e.g. , presence hepatitis B surface antigen ( HBsAg ) positive hepatitis C antibody test result screen within 3 month prior first dose study treatment ] acceptable subject otherwise meet entry criterion ) . ( b ) A severe physical obstruction nose ( e.g. , deviated septum nasal polyp ) frequent bleed nose could affect deposition double blind intranasal study drug . ( c ) Current history Candida infection nose oropharynx , shingle , chickenpox , measles , ocular herpes simplex . ( ) Known hypersensitivity corticosteroid excipients product . ( e ) Recent nasal septal surgery nasal septal perforation . ( f ) Subjects start , discontinue change desensitization treatment within 30 day prior Visit 1 . ( g ) Bacterial viral infection eye upper respiratory tract within two week Visit 1 screening period . ( h ) Asthma , exception mild intermittent asthma . ( ) Diagnosis rhinitis medicamentosa , vasomotor AR eosinophil rhinitis . Abnormal Laboratory Findings : A clinically significant laboratory abnormality include Liver Function Tests Visit 1 meeting follow criterion : Alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent [ % ] ) . Abnormal Electocardiogram ( ECG ) : Clinically significant abnormal ECG find Visit 1 . Significant define : Corrected QT ( QTc ) &gt; 450 millisecond ( msec ) QTc &gt; 480 msec subject Bundle Branch Block . The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trail . Concomitant Medication : Use prescription overthecounter medication would significantly affect course AR , interact study drug , : Chronic use concomitant medication tricyclic antidepressant , would affect assessment effectiveness study drug ; Chronic use long act beta2agonists ( e.g. , salmeterol ) ; Potent Cytochrome P450 subfamily enzyme 3A4 [ CYP3A4 ] inhibitor ( e.g. , ritonavir , ketoconazole , itraconazole , clarithromycin , etc ) ; Allergen immunotherapy treatment allergy . Use followings medication allow throughout study : Shortacting antihistamine , include ocular preparation antihistamine contain anticold medicine , insomnia antalgic ; Oral inhale anticholinergic ; Oral intranasal decongestant ; Oral intranasal antileukotrienes ; Oral inhale longacting beta2 agonist ; Chinese traditional medicine potential effect AR ; Liquorice preparation ; Medications significantly inhibit CYP3A4 , include ritonavir ketoconazole ; tricyclic antidepressant ; longacting antihistamine ( eg . desloratadine , fexofenadine , cetirizine loratadine [ take rescue medication ] ) ; Intranasal antihistamines ; Intranasal ocular cromolyh ; Intranasal corticosteroids include : Inhaled , oral , intramuscular , intravenous , ocular and/or dermatological corticosteroid ( exception hydrocortisone cream/ointment , 1 % less ) Immunosuppressive medication ; Subcutaneous omalizumab . Subjects travel 48 hour study may cause change allergen . Subjects , , opinion Investigator subinvestigators , able comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Seasonal</keyword>
	<keyword>Fluticasone Furoate</keyword>
	<keyword>Perennial</keyword>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Nasal Spray</keyword>
</DOC>